Jump to content

Draft talk:Golam Mohi

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Notability summary for AfC reviewer

[edit]

This draft was prepared by an editor with a declared family conflict of interest and routed through Articles for Creation for independent review. The notability case for WP:NACADEMIC rests on the following points:

  • Continuous NIH R01 funding since 2009, including a $2.4 million R01 awarded in January 2025.
  • Membership on the American Society of Hematology Scientific Committee on Myeloid Neoplasia.
  • Co-Leadership of the Hematologic Malignancies Translational Research Team at the UVA Cancer Center (a NCI-designated cancer center).
  • Direct translation of preclinical work from his laboratory to the multinational Phase 1/2 clinical trial NCT04176198 of TP-3654 (Nuvisertib) for myelofibrosis.
  • More than 4,000 citations on Google Scholar with h-index 25.
  • Leukemia & Lymphoma Society Scholar Award (2013–2018), a competitive five-year award.

Reviewers are welcome to challenge any specific claim or request additional independent secondary sources.